Stock Market Today, October 6, 2026: Dow, S&P 500 and Nasdaq Rise as AI Investment Offsets Macro Risks -( $CEG $EPRX $GOOGL $HPP $MODD $MS $MSFT $MU $NVDA $SER $SOC $SPCX )

U.S. stocks finished higher Tuesday, October 6, 2026, with the S&P 500 gaining 0.58%, the Dow Jones Industrial Average advancing 0.49% and the Nasdaq Composite rising 0.45%. Small-cap stocks lagged, while Treasury yields and volatility declined. AI infrastructure investment remained a major market theme as investors weighed a widening U.S. trade deficit, a long-term nuclear-power agreement involving Alphabet (NASDAQ: GOOG, GOOGL), and ongoing threats to oil shipments through the Strait of Hormuz.

Market Closing Performance

The divergence between rising large-cap benchmarks and a declining Russell 2000 showed that Tuesday’s gains were not uniform across the equity market. The S&P 500 led the three major indexes, while the Nasdaq extended the technology sector’s positive momentum following Monday’s record close.

Bonds, volatility and commodities

The lower Treasury yield and declining VIX accompanied gains in large-cap equities, but the cross-asset picture remained mixed: gold and crude oil rose, Bitcoin slipped, and small caps underperformed. These readings suggest improved sentiment toward major equity benchmarks rather than an across-the-board embrace of risk.

Macroeconomic Report and Commentary

U.S. trade deficit widens

The U.S. goods and services trade deficit increased to $105.6 billion in August, according to the Census Bureau and Bureau of Economic Analysis report released Tuesday. The gap widened by $12.7 billion from July’s revised $92.8 billion deficit, with imports increasing substantially faster than exports.

Source: U.S. Census Bureau and Bureau of Economic Analysis; seasonally adjusted figures.

CNBC reported that the deficit was the largest since March 2025 and exceeded the $102 billion consensus estimate it cited. AI-related imports and tariff-driven shifts in purchasing contributed to the increase. The monthly deterioration should not obscure the longer-term comparison. Through August, the cumulative trade deficit was $138.2 billion smaller than during the corresponding period in 2025, an improvement of 19.9%.

Implications for growth

The wider August deficit creates a potential drag on third-quarter GDP, with reporting on the release indicating that trade remained on track to subtract from growth. However, a larger deficit does not necessarily mean domestic demand is collapsing. Imports associated with AI infrastructure can reflect investment in equipment and computing capacity, even as those purchases worsen the near-term trade balance. The economic question is whether that investment ultimately produces sufficient productivity gains and commercial returns, a distinction between the immediate GDP accounting effect and the longer-term investment outcome.

Rates ease, but remain elevated

The 10-year Treasury yield at 5.27%, down approximately four basis points. That decline coincided with higher major equity indexes and a lower VIX. Ahead of the session, Reuters highlighted elevated long-term borrowing costs and strong expectations for corporate earnings. Its report cited LSEG estimates projecting S&P 500 third-quarter earnings growth of more than 30% year over year, with AI-related companies contributing heavily to the expected increase. For many, the tension remains straightforward: earnings must support valuations while companies navigate financing costs and an increasingly expensive infrastructure buildout. Tuesday’s lower yield offered relief, but the AI revenue outlook remains a separate test of the investment cycle’s durability.

AI and Company Developments

Alphabet secures nuclear power

Google, part of Alphabet (NASDAQ: GOOG, GOOGL), announced a $4.3 billion agreement with Constellation Energy (NASDAQ: CEG) tied to a 20-year power-purchase arrangement. The project is intended to add 890 megawatts of nuclear capacity through upgrades at six existing plants in Illinois, New Jersey and Pennsylvania. The work includes improvements to turbines, steam generators and digital controls across 11 reactors. Constellation Energy (NASDAQ: CEG) also plans to use Google’s Gemini Enterprise technology for activities including site selection, outage management and infrastructure protection. The agreement illustrates how AI investment reaches beyond processors and software into the physical systems required to support computing demand. Reliable electricity is becoming a strategic component of the AI expansion story, alongside access to chips and data-center capacity.

Anthropic expands startup program

Privately held Anthropic expanded its Claude Startups program, seeking deeper relationships with founders and fast-growing businesses. The initiative includes up to $45,000 in discounts and credits through its startup tool package, a one-time $1,000 API credit for eligible organizations, and a free year of Claude Team for up to five premium seats.. The commercial significance is customer adoption. Encouraging startups to build products around Claude could help Anthropic turn model capabilities into recurring usage and longer-term business relationships. That is an interpretation of the program’s strategy, not a reported revenue outcome.

AI faces a revenue test

A Bain & Company analysis reported by Yahoo Finance estimated that the AI industry could require as much as $6 trillion in annual revenue by 2031 to sustain its global infrastructure buildout. Currently identified consumer and enterprise AI products could generate $1.2 trillion to $1.8 trillion, according to the report’s projections, leaving a substantial gap for additional applications to fill. These are scenario-based estimates rather than guaranteed outcomes. The analysis argues that new use cases and broader adoption must develop alongside expanding infrastructure capacity. For companies discussed in the report, including Nvidia (NASDAQ: NVDA), Microsoft (NASDAQ: MSFT) and Micron Technology (NASDAQ: MU), the issue is not simply whether AI spending continues, but whether end customers generate enough value to sustain it. Infrastructure demand and profitable adoption are related, but they are not interchangeable.

SpaceX draws bullish attention

SpaceX (NASDAQ: SPCX) advanced during Tuesday trading following a gain of more than 7% Monday, according to Yahoo Finance. Morgan Stanley (NYSE: MS) analyst Adam Jonas reiterated an Outperform rating and a $300 price target, citing Starship milestones and potential AI-related business opportunities. The report’s roughly 1.5% Tuesday move was an intraday observation. The supplied closing snapshots do not include SpaceX (NASDAQ: SPCX), so its final daily return is not stated here. The analyst’s price target is an opinion about future value, not an assured outcome.

Oil Risks and Investor Focus

November crude oil futures rose 0.54% to $89.91 in the supplied snapshot, reversing the softer early-session oil backdrop described in market reporting. CNBC reported that renewed attacks on commercial ships threatened a fragile recovery in oil exports through the Strait of Hormuz. Nearly 20 commercial vessels, mostly tankers, had come under attack over the preceding month across Hormuz and nearby waters. Kpler data cited by CNBC showed crude shipments through the strait averaging approximately 10.3 million barrels per day in the week ended Saturday, about 23% below the report’s prewar baseline of 13.5 million barrels per day. Recovering shipment volumes do not necessarily mean normal shipping conditions. Insurance costs, freight charges and additional vessel transfers can keep delivered energy expensive even as more oil reaches buyers, limiting the inflation relief from improved supply. The next tests for markets include:

• Corporate earnings: Results must substantiate the strong profit-growth expectations supporting equities.
• AI monetization: Customer adoption and new applications must develop alongside infrastructure commitments.
• Market breadth: Tuesday’s Russell 2000 decline contrasted with gains across the major large-cap indexes.
• Trade and growth: The August deficit adds a potential headwind to third-quarter GDP.
• Energy security: Higher export volumes through Hormuz have not eliminated shipping risks.

VP Watchlist Updates

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $12.27.

AMWL announced (Sept 8) announced the Department of Veterans Affairs (VA) has declared its intent for the Company to deploy its virtual health platform within the VA enterprise and help power the modernization of the VA’s digital health infrastructure. The VA anticipates the Amwell platform will support a broad range of clinical services, enhance care coordination, and improve access for our Veterans across the VA enterprise. The Letter of Intent follows a comprehensive evaluation process by the VA, in which it determined that Amwell’s virtual health platform aligns with the Department’s strategic objectives to expand access to high-quality, secure, and reliable virtual care services for Veterans nationwide through the VA’s current electronic health record modernization efforts. Specifically, the capabilities Amwell demonstrated in scalable video consultations, interoperability, cybersecurity compliance, and support for integrated care delivery were significant factors in this determination.

Amwell® has received Frost & Sullivan’s 2026 United States Technology Innovation Leadership Recognition in the Technology-Enabled Care Platforms Industry. The recognition validates Amwell’s ability to address healthcare fragmentation through a unified platform that orchestrates consumer experiences, clinician workflows, care programs, and partner solutions.

The Company also reiterated recently its objective to achieve positive cash flow from operations in the fourth quarter of 2026.

Serina Therapeutics (NYSE: SER)

Serina Theraeuptics (NYSE: SER, $2.04) is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.

On Thursday, September 24, 2026, Serina CEO Steve Ledger discussed discuss Serina’s programs’ progress during Tribe Public’s “A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress”webinar, followed by a live Q&A. You may view it below.

SER announced (Sept. 9) that the independent Safety Monitoring Committee (SMC) has completed its blinded review of Cohort 1 of the ongoing Phase 1b registrational study of SER-252 in patients with advanced Parkinson’s disease and recommended that the study advance to Cohort 2. Cohort 1 evaluated the lowest dose level in the single-ascending-dose portion of the study. In addition to supporting continued dose escalation, blinded Cohort 1 observations showed a pharmacokinetic profile consistent with the sustained apomorphine exposure SER-252 is designed to provide and included sustained periods of improvement in motor function in individual patients on exploratory clinical measures.

Hudson Pacific Properties (NYSE: HPP)

Hudson Pacific Properties (NYSE: HPP, $11.58, +2.93%) is a real estate investment trust serving dynamic tech and media tenants in global epicenters for these synergistic, converging and secular growth industries. Hudson Pacific’s unique and high-barrier tech and media focus leverages a full-service, end-to-end value creation platform forged through deep strategic relationships and niche expertise across identifying, acquiring, transforming and developing properties into world-class amenitized, collaborative and sustainable office and studio space.

HPP announced (Oct. 5) that its operating partnership, Hudson Pacific Properties, L.P. (the “Company”), has commenced an offer to purchase for cash (the “Tender Offer”) up to a combined aggregate principal amount of $200,000,000 (the “Aggregate Maximum Tender Offer Amount”) of the Company’s outstanding 3.950% Senior Notes due 2027 (the “2027 Notes”) and 5.950% Senior Notes due 2028 (the “2028 Notes” and together with the 2027 Notes, the “Notes” and each a “Series” of Notes) as shown in the linked story, subject to the Allocation Procedures, including the Proration Factor (each as defined below). The Company is offering to purchase $100,000,000 aggregate principal amount of each Series of Notes (the “Target Allocation”).

HPP turned in a quarter ( Aug. 5) that suggests the office malaise is not over, but it may finally be meeting resistance. Revenue came in above Wall Street’s expectations, occupancy moved higher for a fourth straight quarter, and management raised full-year guidance, a combination that does not make for a triumphant victory lap, but it does make for a more credible turnaround narrative. Learn more.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $7.74), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, has added a potentially important chapter to its eosinophilic esophagitis, or EoE, story: a single administration of its investigational localized therapy, EP-104GI, continued to show clinical-remission signals at 52 weeks in the highest-dose cohorts of the ongoing RESOLVE study. For a chronic disease in which swallowing can become a calculated exercise rather than an automatic human function, durability is more than a tidy line on a clinical slide. It is central to the value proposition. The latest data suggest Eupraxia’s localized, extended-release approach may be building toward a differentiated position in a market already led by a formidable incumbent: Sanofi S.A. (NASDAQ: SNY) and its biologic franchise, Dupixent. The clinical data remain early, open-label, and small in patient count, biotech investors should keep both feet on the ground, even when the data seem to float, but the one-year observations give EPRX a meaningful argument for continued investor attention ahead of interim randomized Phase 2b results expected in December 2026.

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $2.73, +18.70%), a commercial-stage medical device company preparing for the commercial launch of its next-generation Pivot™ tubeless patch pump, announced (September 4) that it has secured a contract with a national U.S. pharmacy benefit manager (PBM) in the United States. Pursuant to the contract, the Company’s Pivot insulin delivery system is now available through the national PBM. The Company believes the engagement with this national PBM represents a significant step forward in broadening patient access to the Company’s Pivot tubeless patch pump and will further validate the Pivot pump as an accessible therapeutic option for people living with diabetes.

MODD announced (September 3) that the U.S. Food & Drug Administration (FDA) has cleared a set of software enhancements to its Pivot insulin delivery system, further expanding the system’s functionality and providing users with greater flexibility and customization options in bolus dosing, an enhanced user-interface (UI), and other software upgrades.

MODD CEO, Jeb Besser, co-hosted a Tribe Public’s CEO Presentation and Q&A Webinar Event titled “The Road To Revenue: Modular Medical’s Strategy For Launching Pivot,” that was held Friday, September 4, 2026 (8:30am PT / 11:30 am ET). You may watch the event video below now if you missed it below now.

MODD announced (Aug. 3) plans to initiate the first phase of commercialization of its Pivot tubeless patch pump across five strategically selected U.S. markets beginning in October 2026. The initial rollout will include Atlanta, Cincinnati/Lexington, Dallas, Houston, and Philadelphia, representing a foundational step in the Company’s capital efficient commercialization strategy with its mission to expand access to simplified insulin delivery solutions for all people living with diabetes.

MODD recently (July 22) announced the formation of its Pivot Innovation Council, a cross-functional group of leading clinicians and healthcare experts established to help guide the company’s clinical and commercial strategy. Diabetes care expert Robert Gabbay, MD, PhD, FACP was appointed as chair of the Pivot Innovation Council. The council will provide insights on target patient populations, support optimization of clinical workflows, inform evidence-generation initiatives, and help refine the Pivot product roadmap and go-to-market approach, as the Company continues to scale its differentiated offering.

Modular released findings (July 15) from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy channel.

LG Display Co., Ltd. (LPL)

LG Display Co., Ltd. (NYSE: LPL, $3.09) has spent the last few years doing something many hardware companies talk about but few execute well: turning a technology pivot into a full‑blown business transformation that everyday investors can actually follow. Instead of chasing commoditized LCD TV panels in a race to the bottom, LPL is leaning into Gaming OLED, CES‑worthy innovation, and premium automotive displays – and the press trail tells a surprisingly investor‑friendly story.

Yatsen Group (NYSE: YSG)

Yatsen Group (NYSE: YSG, $2.56), a leading China-based beauty group, delivered the sort of quarter that can make a turnaround investor sit up straighter: reported revenue grew, its strategically important skincare operation accelerated sharply, and the company is increasingly built around clinical and premium brands rather than a pure color-cosmetics play. The results are not yet a victory lap, losses widened and third-quarter guidance is cautious, but YSG’s transformation is beginning to look less like a cosmetic touch-up and more like a genuine renovation.

YSG announced (July 8) a landmark collaboration to bring its flagship brand, Perfect Diary, to Sephora in China. This partnership integrates Yatsen’s rigorous scientific infrastructure with the world’s leading prestige beauty retailer, marking a significant milestone in Yatsen’s continuing evolution into a global beauty technology powerhouse.

Doximity, Inc. (NYSE:DOCS)

Doximity (NYSE: DOCS, $27.79) is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.

DOCS announced (Sept. 22) that it has been named a founding partner in the launch of a new Specialized Intelligence Index of leading AI benchmarks compiled by Fireworks, the AI training and inference platform. As part of the launch, Doximity is publishing a new open-source benchmark for measuring clinical-grade AI. Called Bedside Bench, the benchmark has been built to test AI’s ability to be a trusted partner to doctors where it matters most: at the bedside.

Doximity, Inc. (NYSE: DOCS) announced (Aug. 6) results of its fiscal 2027 first quarter ended June 30, 2026. Jeff Tangney, co-founder and CEO of Doximity, “We’re proud that our clinical AI assistant, Doximity Ask, was the top-performing U.S.-based model in the NOHARM benchmark while we delivered another quarter of record engagement. In Q1 we had accelerated revenue growth along with workflow active prescriber growth of more than 30% year-over-year and AI Search query growth of over 25% quarter-over-quarter.”

Fiscal 2027 First Quarter Financial Highlights

All comparisons, unless otherwise noted, are to the three months ended June 30, 2025.

• Revenue: Revenue of $156.6 million, versus $145.9 million, an increase of 7% year-over-year.
• Net income and non-GAAP net income: Net income of $24.3 million, versus $53.3 million, representing a margin of 15.5%, versus 36.5%. Non-GAAP net income of $55.0 million, versus $71.9 million, representing a margin of 35.1%, versus 49.2%.
• Adjusted EBITDA: Adjusted EBITDA of $74.8 million, versus $79.8 million, a decrease of 6% year-over-year, representing adjusted EBITDA margins of 47.7%, versus 54.7%.
• Diluted net income per share and non-GAAP diluted net income per share: Diluted net income per share was $0.13, versus $0.27, while non-GAAP diluted net income per share was $0.29, versus $0.36.
• Operating cash flow and free cash flow: Operating cash flow of $42.0 million, versus $62.1 million, a decrease of 32% year-over-year, and free cash flow of $39.6 million, versus $60.1 million, a decrease of 34% year-over-year.

Financial Outlook

Doximity is providing guidance for its fiscal second quarter ending September 30, 2026 as follows:

• Revenue between $170 million and $171 million.
• Adjusted EBITDA between $80.5 million and $81.5 million.

Doximity is updating guidance for its fiscal year ending March 31, 2027 as follows:

• Revenue between $671 million and $681 million.
• Adjusted EBITDA between $309 million and $329 million.

Sable Offshore Corp. (SOC)

Sable Offshore Corp. (NYSE: SOC, $3.57, +2.88%). JPMorgan Chase (NYSE: JPM) initiated coverage of Sable Offshore (NYSE: SOC) with an Overweight rating and a $10 price target October 2. That target implies an approximately 178% gain from today’s prices that are in the $3.59 range. It is an attention-getting valuation gap, even by the standards of an industry accustomed to looking beneath the surface. The more substantive opportunity, however, lies offshore California. Sable is already generating revenue from its Santa Ynez Unit, while preparing to restart Platform Hondo and expand the infrastructure needed to move more oil to market. The bullish thesis is therefore more advanced than a bet on dormant assets: it is a wager for many that an operating business can overcome its remaining bottlenecks and convert additional barrels into stronger cash generation.

Nvidia (NVDA, $239.24, +.14%)

NVIDIA Corp. (NASDAQ: NVDA). AM Intelligence (“AMI”), the AI infrastructure platform set up by Promoters of Greenko, announced (Oct. 5) two further firm and binding orders for 20,000 NVIDIA Rubin GPUs, to be deployed as NVIDIA Vera Rubin NVL72 rack-scale systems. Building on its first AI factory in Hyderabad, the expansion is designed to give cloud providers, enterprises and AI developers access to large-scale computing capacity closer to where they build and deploy AI.

NVDA recently has seemingly has given many a two-part bullish signal: a record-sized $150 billion increase to its share-repurchase authorization and a new AI-agent safety platform aimed at making autonomous software more secure for enterprise deployment. The combination suggests a company using extraordinary financial strength not merely to reward shareholders, but to expand its influence from AI computing into the governance, security and operating layer of the AI economy. The timing is notable. Markets are beginning the week with a cautiously constructive tone, even as investors brace for jobs, inflation and manufacturing data that could reset the outlook for interest rates. In that environment, NVIDIA is making a familiar but potent argument: its AI franchise is generating enough cash to finance innovation, deepen its ecosystem and return meaningful capital to shareholders, all at once. That is not an everyday corporate trick. It is closer to juggling bowling balls while also building the bowling alley.

The Sources

1. CNBC Stock market live updates, October 6, 2026.
2. U.S. Bureau of Economic Analysis U.S. International Trade in Goods and Services, August 2026.
3. CNBC Trade deficit hits $105.6 billion, widest since just before Trump tariffs enacted last year.
4. Transport Topics U.S. Trade Gap Widens to $105.6 Billion as Imports Hit Record.
5. Reuters October 6, 2026, Wall Street market report.
6. Yahoo Finance Stock market today: Dow, S&P 500, Nasdaq.
7. Yahoo Finance Google signs 20-year nuclear deal with Constellation Energy to power AI build-out.
8. CNBC Anthropic expands Claude Startups program in bid to snag founders and fast-growing companies.
9. Yahoo Finance AI industry needs to rake in $6 trillion in sales by 2031 to sustain its global build-out: Report.
10. Yahoo Finance SpaceX stock climbs higher, poised for another multimonth closing high.
11. CNBC Rebounding oil exports through Strait of Hormuz are vulnerable to stepped-up Iranian tanker attacks.